Foghorn Therapeutics Advances FHD-909 Phase 1 Trial

An announcement from Foghorn Therapeutics ( (FHTX) ) is now available.

In May 2025, Foghorn Therapeutics provided a financial and corporate update, highlighting the advancement of its FHD-909 Phase 1 trial targeting SMARCA4 mutated cancers, with non-small cell lung cancer as the primary focus. The company also presented promising preclinical data at the AACR Annual Meeting, showcasing the potential of FHD-909 in combination with other cancer therapies. Additionally, Foghorn announced progress in its Selective CBP and EP300 degrader programs, with updates expected in the latter half of 2025. The company maintains a strong financial position with a cash runway into 2027, supporting its ongoing strategic collaboration with Lilly and the development of novel oncology medicines.

The most recent analyst rating on (FHTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.

Spark’s Take on FHTX Stock

According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.

Foghorn Therapeutics receives a low overall score due to significant financial instability, negative profitability, and bearish technical indicators. However, recent positive corporate developments and advancements in drug development provide some optimism, slightly offsetting negative factors.

To see Spark’s full report on FHTX stock, click here.

More about Foghorn Therapeutics

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines that treat serious diseases by correcting abnormal gene expression. With an initial focus on oncology, the company utilizes its Gene Traffic Control® Platform to create a broad pipeline aimed at transforming the lives of people suffering from a wide spectrum of diseases.

Average Trading Volume: 127,704

Technical Sentiment Signal: Sell

Current Market Cap: $246.8M

Learn more about FHTX stock on TipRanks’ Stock Analysis page.